Evaluation of the effects of oral water and low-density barium sulphate suspension on bowel appearance on FDG-PET/CT.
The purpose of this study is to assess which of five bowel preparation regimes offers superior bowel distension and to assess if these regimes adversely affect FDG activity on PET/CT imaging. The study conformed to HIPAA regulations. Ninety patients were divided into five groups of 18 who received no oral contrast agent (group A); 900 ml of water orally (group B); or 900, 1,350, or 1,800 ml of LDB (groups C, D, E, respectively). PET/CT examinations were assessed quantitatively (bowel diameter, SUV) and qualitatively (visual assessment grading scale) for bowel distension and FDG activity by two blinded readers. ANOVA was utilized to determine if a statistically significant difference (SSD) existed between the groups in terms of distension and FDG uptake. Qualitatively superior bowel distension was observed in group C (LDB) compared to B (water) and greater distension was noted with increased volumes of LDB in C, D, and E. Quantitatively there was an SSD in mean distension between groups C and B (P < 0.001 except duodenum). Qualitatively and quantitatively there was no significant difference in bowel FDG uptake among the groups (P > 0.05). LDB as an oral contrast agent provides superior bowel distension over water and does not induce increased FDG bowel activity.
Blake
Michael A
MA
Department of Radiology, Division of Abdominal Imaging and Interventional Radiology, Massachusetts General Hospital, White 270, 55 Fruit Street, Boston, MA 02114, USA.
Setty
Bindu N
BN
Cronin
Carmel G
CG
Kalra
Mannudeep
M
Holalkere
Nagaraj Setty
NS
Fischman
Alan J
AJ
Mueller
Peter R
PR
Sahani
Dushyant V
DV
D000284:Administration, Oral; D001466:Barium Sulfate / Q000008:administration & dosage; D003287:Contrast Media / Q000008:administration & dosage; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D008297:Male; D008970:Molecular Weight; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013382:Subtraction Technique; D014057:Tomography, X-Ray Computed / Q000379:methods*; D014867:Water / Q000008:administration & dosage
D003287:Contrast Media; D019275:Radiopharmaceuticals; D014867:Water; D019788:Fluorodeoxyglucose F18; D001466:Barium Sulfate
Invest Radiol. 2003 Dec;38(12):784-9
14627896
Radiology. 2006 Jan;238(1):87-95
16293806
Radiology. 2004 Mar;230(3):879-85
14764889
Radiology. 2004 Feb;230(2):417-22
14699176
Radiology. 1996 Nov;201(2):365-70
8888224
Abdom Imaging. 2006 Jan-Feb;31(1):48-53
16252139
Eur J Nucl Med Mol Imaging. 2005 Oct;32(10):1160-6
15937685
Eur J Nucl Med. 2001 Dec;28(12):1766-9
11734913
Radiology. 1999 Jun;211(3):870-5
10352618
AJR Am J Roentgenol. 2005 Aug;185(2):495-500
16037527
Ann Nucl Med. 2005 Apr;19(2):101-8
15909489
AJR Am J Roentgenol. 2002 Aug;179(2):477-81
12130457
AJR Am J Roentgenol. 2002 Dec;179(6):1555-60
12438054
J Nucl Med. 2003 Mar;44(3):412-6
12621008
Rofo. 2005 Jun;177(6):796-9
15902627
Clin Positron Imaging. 2000 Jul;3(4):178
11150781
Clin Positron Imaging. 2000 Nov;3(6):223-230
11378434
Curr Opin Radiol. 1992 Jun;4(3):93-104
1581139
Acad Radiol. 2003 May;10(5):491-6
12755536